Work

Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.5012

Authors: T. K. Choueiri, S. A. Vaziri, B. I. Rini, P. Elson, I. Bhalla, E. Jaeger, V. Weinberg, F. M. Waldman, M. Zhou, R. M. Bukowski, R. Ganapathi

Institutions: Cleveland Clinic, University of California, San Francisco

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2964708379

Cites:

Cited by: 28

Related to: 10